6-Mercaptopurine is an anti-cancer chemotherapy drug classified as an antimetabolite. In this study, the impact of the Trivedi Effect® (Consciousness Energy Healing Treatment) on the structural properties and the isotopic abundance ratio of 6-mercaptopurine were evaluated using LC-MS and GC-MS spectroscopy. The test sample 6-mercaptopurine was divided and termed as control and Biofield Energy Treated sample. The treated part of the sample only received the Trivedi Effect®-Consciousness Energy Healing Treatment remotely by a renowned Biofield Energy Healer, Dahryn Trivedi. The LC-MS spectra of both the samples at retention time (Rt) 2.2 minutes exhibited the mass of the protonated molecular ion peak at m/z 173 [M+H]+ (calculated for C5H5N4S+, 153.18). The peak area of the treated 6-mercaptopurine was significantly increased by 94.62% compared to the control sample. The LC-MS based isotopic abundance ratio of PM+1/PM in the treated mercaptopurine was significantly increased by 107.92% compared with the control sample. Similarly, the GC-MS based isotopic abundance ratio of PM+2/PM in the treated 6-mercaptopurine was significantly increased by 25.78% compared with the control sample. Thus,13C, 2H, 15N, 33S, and 18O contributions from (C5H5N4S)+ to m/z 154 in the treated sample were significantly increased compared with the control sample. The isotopic abundance ratio of PM+1/PM (2H/1H or 13C/12C or 15N/14N or 33S/32S) and PM+2/PM (34S/32S) in the treated 6-mercaptopurine was significantly improved compared to the control sample. The significant increase in the peak area, isotopic abundance and mass peak intensities could be due to changes in nuclei possibly happened due to the interference of neutrino particles via the Trivedi Effect®. The increased isotopic abundance ratio of the treated sample would improve the strength of the chemical bond, increase the physical and chemical stability of 6-mercaptopurine in the body. The nove l6-mercaptopurine would be better designing more efficacious pharmaceutical formulations that might offer better more bioavailability and therapeutic response against acute lymphocytic leukemia, chronic myeloid leukemia, Crohn’s disease, and ulcerative colitis, etc.
